Search - tctmd.com

Displaying 961 - 980 of 1300

Sort: Relevancy | Date

News Daily News

Bivalirudin Shows Advantage Over GPIs—But Not Heparin Alone—in STEMI Patients

L.A. McKeown

November 28, 2012

Presentation

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

Presenter: S. Cassese

November 26, 2012

Presentation

Bivalirudin for Primary PCI

Presenter: B. Hibbert

November 26, 2012

News Daily News

Study Shows Impact of Public Health Communication on Clopidogrel Use Post DES

November 20, 2012

News Daily News

Estudio muestra el impacto de la comunicación de salud pública en el uso de clopidogrel después de la colocación de un SLF

November 20, 2012

Presentation

Evaluating the Impact of Public Health Notification: Duke Clopidogrel Experience

Presenter: Eric L. Eisenstein

November 19, 2012

News Daily News

Una Dosis Alta de Atorvastatina podría prevenir la Lesión Renal inducida por Contraste en las PCI Voluntarias

L.A. McKeown

November 18, 2012

News Daily News

High Dose Atorvastatin May Prevent Contrast-Induced Kidney Injury in Elective PCI

L.A. McKeown

November 18, 2012

Presentation

Impact of a High Loading Dose of Atorvastatin on Contrast-Induced Acute Kidney Injury

Presenter: C. Quintavalle

November 15, 2012

News Daily News

Risk Peaks Early After Clopidogrel Cessation in SVG PCI Patients

November 13, 2012

Presentation

Discontinuation of Long-term Clopidogrel Therapy Is Associated with Death and MI After SVG PCI

Presenter: A. Sachdeva

November 13, 2012

News Conference News AHA 2012

Evidence Continues to Support Dabigatran Treatment in A-fib

November 06, 2012

News Conference News AHA 2012

No Mortality Benefit with Prolonged Dual Antiplatelet Therapy

November 05, 2012

News Conference News TCT 2012

Aspirin, Cilostazol Combination Best After Angioplasty for Critical Limb Ischemia

November 01, 2012

Presentation TCT 2012

Part 2: Antiplatelet Agents

Presenter: Robert Harrington

October 25, 2012

Presentation TCT 2012

Part 1: Oral Anticoagulants

Presenter: Christopher Granger

October 25, 2012

Presentation TCT 2012

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Presenter: Rajesh Dave

October 25, 2012

$Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!$

Presentation TCT 2012

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Gilles Montalescot

October 25, 2012

Presentation TCT 2012

Debate: Clopidogrel is Enough and Still Plays a Role for Most!

Presenter: Michael Love

October 25, 2012

Presentation TCT 2012

Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!

Presenter: Roxana Mehran

October 25, 2012

Advertisement

Bivalirudin Shows Advantage Over GPIs—But Not Heparin Alone—in STEMI Patients

Meta-analysis: Clinical Impact of Extended DAPT After PCI in the DES Era

Bivalirudin for Primary PCI

Study Shows Impact of Public Health Communication on Clopidogrel Use Post DES

Estudio muestra el impacto de la comunicación de salud pública en el uso de clopidogrel después de la colocación de un SLF

Evaluating the Impact of Public Health Notification: Duke Clopidogrel Experience

Una Dosis Alta de Atorvastatina podría prevenir la Lesión Renal inducida por Contraste en las PCI Voluntarias

High Dose Atorvastatin May Prevent Contrast-Induced Kidney Injury in Elective PCI

Impact of a High Loading Dose of Atorvastatin on Contrast-Induced Acute Kidney Injury

Risk Peaks Early After Clopidogrel Cessation in SVG PCI Patients

Discontinuation of Long-term Clopidogrel Therapy Is Associated with Death and MI After SVG PCI

Evidence Continues to Support Dabigatran Treatment in A-fib

No Mortality Benefit with Prolonged Dual Antiplatelet Therapy

Aspirin, Cilostazol Combination Best After Angioplasty for Critical Limb Ischemia

Part 2: Antiplatelet Agents

Part 1: Oral Anticoagulants

Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice?

Debate: Enoxaparin or Unfractionated Heparin Plus/Minus Glycoprotein IIb/IIIa Inhibitors Is the Preferred Anticoagulant Strategy During STEMI!

Debate: Clopidogrel is Enough and Still Plays a Role for Most!

Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content